Keros Therapeutics director Prener sells 574 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Keros Therapeutics, Inc. (KROS) director Anne Prener sold 574 shares of common stock at $9.79 per share on November 12, 2026. The sale was made under a Rule 10b5-1 trading plan adopted August 6, 2026. She directly held 13,212 shares after the sale.
Insider Trade Summary 10b5-1
Net Seller: 574 shares
Net Sell
1 txn
Insider
Prener Anne
Role
Director
Sold
574 shs ($6K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 574 | $9.79 | $6K |
Holdings After Transaction:
Common Stock — 13,212 shares (Direct)
Footnotes (1)
- F1. The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2026.
Key Figures
Shares sold: 574 shares
Sale price: $9.79 per share
Direct shares held after sale: 13,212 shares
3 metrics
Shares sold
574 shares
Common stock sold on November 12, 2026
Sale price
$9.79 per share
Sale on November 12, 2026
Direct shares held after sale
13,212 shares
Anne Prener's reported direct holdings following the November 12, 2026 sale
Key Terms
Rule 10b5-1 trading plan
1 terms
Rule 10b5-1 trading plan regulatory
"under a Rule 10b5-1 trading plan adopted August 6, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.